New combo therapy aims to reverse liver damage in hepatitis b patients
NCT ID NCT07183293
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether adding peginterferon alfa-2b to standard antiviral drugs can improve liver health in people with compensated cirrhosis caused by hepatitis B. Thirty adults will be randomly assigned to receive either the combination or antivirals alone for 48 weeks. Researchers will measure changes in liver scarring, stiffness, and the risk of liver cancer or liver failure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- peginterferon alfa-2b combined with nucleoside analogues (antiviral drugs)
- What this could lead to
- If successful, this combination could offer a better way to slow or reverse liver damage and lower the risk of liver cancer in people with hepatitis B-related cirrhosis.
- What could go wrong
- This is a small, early-phase study with only 30 participants, so results may not apply broadly. Peginterferon can cause flu-like symptoms and other side effects, and the added benefit over standard antivirals alone is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HBV-RELATED LIVER CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Xiamen Hospital of Traditional Chinese Medicine
Xiamen, China
-
Zhongshan Hospital Affiliated to Xiamen University
Xiamen, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.